Prostate volume and adverse prostate cancer features: Fact not artifact

European Journal of Cancer

Volumn 43, Issue 18, 2007, Pages 2669-2677

  Briganti, Alberto ^a,b   Chun, Felix K H ^a,c   Suardi, Nazareno ^a,b   Gallina, Andrea ^a,b   Walz, Jochen ^a,c   Graefen, Markus ^c   Shariat, Shahrokh ^a   Ebersdobler, Andreas ^c   Rigatti, Patrizio ^b   Perrotte, Paul ^a   Saad, Fred ^a   Montorsi, Francesco ^b   Huland, Hartwig ^c   Karakiewicz, Pierre I ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

High grade prostate cancer; Prostate cancer; Prostate volume

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; TUMOR BIOPSY;

ADULT; AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ORGAN SIZE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SEMINAL VESICLES;

EID: 36349014841     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.09.022     Document Type: Article

References (23)

1. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
2. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
3. Karakiewicz P.I., Bazinet M., Aprikian A.G., et al. Outcome of sextant biopsy according to gland volume. Urology 49 (1997) 55-59
4. Uzzo R.G., Wei J.T., Waldbaum R.S., et al. The influence of prostate size on cancer detection. Urology 46 (1995) 831-836
5. Freedland S.J., Isaacs W.B., Platz E.A., et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 23 (2005) 7546-7554
6. Kulkarni G.S., Al-Azab R., Lockwood G., et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175 (2006) 505-509
7. Henke R.P., Kruger E., Ayhan N., et al. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 152 (1994) 1297-1301
8. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988) 897-906
9. Thompson I.M., Basler J., Hensley D., et al. Prostate cancer prevention: what do we know now and when will we know more?. Clin Prostate Cancer 1 (2003) 215-220
10. Marberger M., Adolfsson J., Borkowski A., et al. The clinical implications of the prostate cancer prevention trial. BJU Int 92 (2003) 667-671
11. Luo J., Dunn T.A., Ewing C.M., Walsh P.C., and Isaacs W.B. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57 (2003) 134-139
12. Thompson I.M., Klein E.A., Lippman S.M., Coltman C.A., and Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 44 (2003) 650-655
13. Imamov O., Lopatkin N.A., and Gustafsson J.A. Estrogen receptor beta in prostate cancer. N Engl J Med 351 (2004) 2773-2774
14. Higgins B, Thompson IM. The Prostate Cancer Prevention Trial: current status. J Urol 2004;171:S15-7; discussion S8.
15. Bostwick D.G., Qian J., Civantos F., Roehrborn C.G., and Montironi R. Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer 2 (2004) 228-235
16. Mellon J.K. The finasteride prostate cancer prevention trial (PCPT)-what have we learned?. Eur J Cancer 41 (2005) 2016-2022
17. Lotan Y., Cadeddu J.A., Lee J.J., Roehrborn C.G., and Lippman S.M. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 23 (2005) 1911-1920
18. Unger J.M., Thompson Jr. I.M., LeBlanc M., et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer 103 (2005) 1375-1380
19. Andriole G., Bostwick D., Civantos F., et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 174 (2005) 2098-2104
20. Chen M.E., Troncoso P., Johnston D., Tang K., and Babaian R.J. Prostate cancer detection: relationship to prostate size. Urology 53 (1999) 764-768
21. Thompson I.M., Tangen C.M., Goodman P.J., et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 177 (2007) 1749-1752
22. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
23. Serfling R., Shulman M., Thompson G.L., et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 177 (2007) 2352-2356